-
-
Call more information
660-596-2224 -
ASA Monitor November 2023, Vol. 87, 36. ASA guidance on popular diabetes and weight-loss medications receives coverage in top outlets Starting in June, ASA received historic media coverage when it released guidance to withhold glucagon-like peptide-1 (GLP-1) receptor agonists used for diabetes and weight loss (such as Ozempic® and Wegovy®) before elective surgery to reduce the […]
Read MoreASA Monitor November 2023, Vol. 87, 32. Variable response to sugammadex (June 2023) The sugammadex doses recommended for reversal of neuromuscular block are based on the train-of-four response to nerve stimulation. However, the efficacy varies with such fixed doses. In a prospective study of 97 surgical patients who received rocuronium for paralysis, 13% had residual neuromuscular […]
Read MoreAuthor: Madeline Talbot ASA Monitor November 2023, Vol. 87, 30. There’s a reason why medical dramas have dominated the television sphere for decades: the hospital presents the perfect setting for considerable clashes between individuals, with high consequences. Determining whether an individual’s behavior is disruptive or just unfavorable can be challenging, but there are resources and guidelines […]
Read MoreAuthors: Gordon Morewood, MD, MBA, FASA et al ASA Monitor November 2023, Vol. 87, 1–9. The ASA Committee on Economics is pleased to present the results of the 2023 commercial conversion factor (CF) survey. Each spring, ASA members are solicited to submit the CFs from their group practice’s five largest commercial contracts. This year, both the […]
Read MoreAuthor: Jim Fehr, MD, FAAP ASA Monitor November 2023, Vol. 87, 33. We miss one of the most exciting moments of our lives – our birth. From that first day on, humans learn and accumulate experiences and dream about great things to come. It is a pediatric anesthesiologist’s honor and pleasure to be present with families […]
Read More